Provided by Tiger Trade Technology Pte. Ltd.

CINGULATE INC.

6.39
+0.11001.75%
Post-market: 6.21-0.1800-2.82%19:57 EDT
Volume:370.69K
Turnover:2.29M
Market Cap:74.31M
PE:-1.44
High:6.43
Open:6.21
Low:5.99
Close:6.28
52wk High:11.89
52wk Low:3.20
Shares:11.63M
Float Shares:10.72M
Volume Ratio:0.59
T/O Rate:3.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.4408
EPS(LYR):-10.1953
ROE:-450.60%
ROA:-83.25%
PB:29.62
PE(LYR):-0.63

Loading ...

Company Profile

Company Name:
CINGULATE INC.
Exchange:
NASDAQ
Establishment Date:
2012
Employees:
14
Office Location:
1901 West 47th Place,Kansas City,Kansas,United States
Zip Code:
66205
Fax:
- -
Introduction:
Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

Directors

Name
Position
John A. Roberts
Chairman and Director
Bryan Lawrence
Director
Jeff Hargroves
Director
Jeffrey S. Ervin
Director
Peter J. Werth
Director

Shareholders

Name
Position
Shane J. Schaffer
Chief Executive Officer
Jennifer L. Callahan
Chief Financial Officer and Executive Vice President and Secretary
Bryan Downey
Chief Commercial Officer and Executive Vice President
Matthew N. Brams
Chief Medical Officer and Executive Vice President
Nilay D. Patel
Chief Compliance Officer and Chief Legal Officer and Executive Vice President
Raul R. Silva
Chief Science Officer and Executive Vice President